Buy Rating Affirmed: Prothena’s Prasinezumab Shows Promise in Slowing Parkinson’s Progression
TipRanks (Thu, 9-May 8:25 AM ET)
RBC Capital Sticks to Their Hold Rating for Prothena (PRTA)
TipRanks (Thu, 9-May 6:53 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Paragon 28 (FNA), Prothena (PRTA)
TipRanks (Thu, 9-May 12:50 AM ET)
Prothena GAAP EPS of -$1.34 misses by $0.12, revenue of $0.05M misses by $2.12M
Seeking Alpha News (Wed, 8-May 5:00 PM ET)
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
Business Wire (Wed, 8-May 4:05 PM ET)
Prothena Q1 2024 Earnings Preview
Seeking Alpha News (Tue, 7-May 5:35 PM ET)
Prothena to Report First Quarter 2024 Financial Results on May 8
Business Wire (Wed, 1-May 4:05 PM ET)
Business Wire (Mon, 15-Apr 4:05 PM ET)
Prothena to Participate in Upcoming Healthcare Conferences
Business Wire (Tue, 5-Mar 4:05 PM ET)
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Business Wire (Mon, 4-Mar 4:05 PM ET)
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Prothena PLC - trades on the NASDAQ stock market under the symbol PRTA.
As of May 9, 2024, PRTA stock price declined to $22.24 with 82,883 million shares trading.
PRTA has a beta of 0.80, meaning it tends to be less sensitive to market movements. PRTA has a correlation of 0.02 to the broad based SPY ETF.
PRTA has a market cap of $1.19 billion. This is considered a Small Cap stock.
Last quarter Prothena PLC - reported $50,000 in Revenue and -$1.34 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.14.
In the last 3 years, PRTA stock traded as high as $79.75 and as low as $19.65.
The top ETF exchange traded funds that PRTA belongs to (by Net Assets): XBI, IWM, VXF, IWO, IBB.
PRTA has underperformed the market in the last year with a return of -71.1%, while the SPY ETF gained +27.3%. In the last 3 month period, PRTA fell short of the market, returning -18.9%, while SPY returned +4.4%. However, in the most recent 2 weeks PRTA has outperformed the stock market by returning +8.2%, while SPY returned +2.6%.
PRTA support price is $22.27 and resistance is $23.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRTA stock will trade within this expected range on the day.